Deca-Durabolin Injection, USP
DIN 00080932
200 mg/mL
10 mL Multiple-Dose, Cartons of 1 vial
DESCRIPTION Deca-Durabolin injection USP, for intramuscular injection, contains Nandrolone Decanoate which is soluble oil (17β)-3-Oxoestr-4-en-17-yl decanoate ester of this anabolic androgenic hormone.
COMPOSITION Medicinal ingredients and Non-Medicinal ingredients. Nandrolone Decanoate, 200mg/mL; benzyl alcohol, 9mg/mL; cottonseed oil q.s
PHARMACOLOGICAL CLASSIFICATION A 21.6 Anabolic Steroids
PHARMACOLOGICAL ACTION Deca-Durabolin is an injectable anabolic preparation. After injection, Nandrolone Decanoate is gradually released from the intramuscular depot and subsequently hydrolyzed into Nandrolone.
INDICATIONS It works as an anabolic steroid. It is used to treat certain cases of disseminated breast cancer in women and osteoporosis due to androgen deficiency in hypogonadal males.
CONTRA-INDICATIONS Not intended for children. Not intended for patients with a known or suspected prostatic carcinoma and mammary carcinoma in the male. Not intended for use in female patients other than those with disseminated breast cancer. Contraindicated in nephrosis or the nephrotic phase of nephritis, cardiac and renal failure, hypercalcaemia, oedema, jaundice, liver disease with impaired bilirubin excretion, testicular, and hepatic carcinoma.
DOSAGE AND ADMINISTRATION Deca-Durabolin should be administered by deep intramuscular injection. Adult dose: 200-400mg weekly
ADVERSE REACTIONS Virilization might occur in sensitive women as hoarseness, acne, hirsutism, and phallic enlargement, and in girls as an increase in pubic hair and clitoral hypertrophy. Hoarseness may be the first symptom of vocal change which may end in a long-lasting, sometimes irreversible deepening of the voice. Other adverse reactions may include: – oligospermia and decreased in the ejaculatory volume; – suppression of ovarian activity, atrophy of the breasts and endometrial tissue; – amenorrhoea and inhibition of spermatogenesis; – water and salt retention; – premature epiphyseal closure; – signs of virilization, if symptoms appear, treatment should be discontinued; – increase in nitrogen retention and skeletal weight; – oedema; – increase in the vascularity of the skin; – increase in the growth of the bone; and – elderly males may become over-stimulated. Patients with the following conditions should be monitored: – latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions), since anabolic steroids may induce salt and fluid retention; – diabetes, since anabolic steroids may increase the glucose tolerance and decrease the need for insulin or other antidiabetic drugs; – incomplete statural growth, since anabolic steroids in high dosages may accelerate epiphyseal closure; – skeletal metastases, since anabolic steroids may induce hypercalcaemia and hypercalciuria to these patients; and – liver dysfunction.
INTERACTIONS Liver-enzyme-inducing agents may reduce the effects of Deca-Durabolin by enhancing the metabolism in the liver.
STORAGE INSTRUCTIONS Vial should be kept away from light and stored in controlled temperature from 20-25 degree Celsius (68° TO 77°F). Warming and shaking the vial should redissolve any crystals that may have formed during storage. Keep out of reach of children.